Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.67 |
| ▸ | STAT6 | P42226 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 6/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14591405 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL58750 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL14568137 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL5980725 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL13682076 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL57979 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL14186137 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL57410 | 1.00 | TUBB1 (0.67) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL6799344 | 0.97 | TUBB1 (0.64) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL6805948 | 0.95 | TUBB1 (0.65) | TUBB1STAT6MMP3CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | claimed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-16 | — | — | US | disclosed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2020-09-24 | — | — | US | disclosed |
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2019-05-23 | — | — | US | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7078572-B2 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050288486-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-12-29 | — | — | US | disclosed |
| US-6951955-B2 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1539682-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | Wyeth Holdings Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2004026814-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | TUBB1 158/4885STAT6 4251/4885MMP3 4288/4885 |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | TUBB1 727/4885STAT6 3649/4885MMP3 4352/4885 |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | PA2G4, FCGRT, CLTB | TUBB1 158/4885STAT6 4251/4885MMP3 4288/4885 |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LPO, NOXO1, DAO | TUBB1 317/4885STAT6 4655/4885MMP3 3839/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885STAT6 2002/4885MMP3 136/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885STAT6 4739/4885MMP3 4096/4885 |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | TUBB1, TUBA1C, TUBB | TUBB1 1/4885STAT6 4840/4885MMP3 3929/4885 |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | TUBB1 158/4885STAT6 4251/4885MMP3 4288/4885 |
| US-20050288486-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | TUBB1, TUBB, TUBA1C | TUBB1 1/4885STAT6 4450/4885MMP3 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.